EUVIMEDEUVIMED entdecken
Crossref

Sorafenib: advances in targeted therapy for renal cell carcinoma

Robert E Hawkins, Fiona C Thistlethwaite

Future Prescriber · 2006

DOI: 10.1002/fps.12 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Prescriber, 2006. Verfasst von Robert E Hawkins und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sorafenib is the first dual action oral multi‐kinase inhibitor to target serine/threonine and receptor tyrosine kinases in both the tumour cell and the tumour vasculature. Phase II studies and now the largest ever phase III study in advanced renal cell cancer suggest that sorafenib will be a valuable new therapy for patients with kidney cancer. Copyright © 2006 John Wiley & Sons, Ltd.

Zitieren

APA

Hawkins, R. E., & Thistlethwaite, F. C. (2006). Sorafenib: advances in targeted therapy for renal cell carcinoma. Future Prescriber. https://doi.org/10.1002/fps.12

Vancouver

Hawkins RE, Thistlethwaite FC. Sorafenib: advances in targeted therapy for renal cell carcinoma. Future Prescriber. 2006. doi:10.1002/fps.12

BibTeX
@article{Hawkins2006,
  author = {Hawkins, Robert E and Thistlethwaite, Fiona C},
  title = {Sorafenib: advances in targeted therapy for renal cell carcinoma},
  journal = {Future Prescriber},
  year = {2006},
  doi = {10.1002/fps.12}
}
Kostenlos starten →